Activity of Abiraterone in Rechallenging Two AR-expressing Salivary Gland Adenocarcinomas, Resistant to Androgen-Deprivation Therapy

Cancer Biology and Therapy - United States
doi 10.4161/cbt.28410
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Androgen Receptor Signaling in Salivary Gland Cancer

Cancers
Cancer ResearchOncology
2017English

Transcription Factors Involved in Prostate Gland Adaptation to Androgen Deprivation

PLoS ONE
Multidisciplinary
2014English

Medical Resource Utilization of Abiraterone Acetate Plus Prednisone Added to Androgen Deprivation Therapy in Metastatic Castration-Naive Prostate Cancer: Results From LATITUDE

Cancer
Cancer ResearchOncology
2018English

Cost-Effectiveness Analysis of Abiraterone, Docetaxel or Placebo Plus Androgen Deprivation Therapy for Hormone-Sensitive Advanced Prostate Cancer

Einstein (São Paulo, Brazil)
Medicine
2019English

Androgen Deprivation Therapy and Cardiovascular Complications

Bratislava Medical Journal
2017English

Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells

Cancer immunology research
Cancer ResearchImmunology
2017English

Androgen Deprivation Therapy for Prostate Cancer

2017English

Adaptive Phenotype Drives Resistance to Androgen Deprivation Therapy in Prostate Cancer

Cell Communication and Signaling
BiochemistryCell BiologyMolecular Biology
2017English

Castration-Resistant Prostate Cancer: A Strategy to Enhance Response to Androgen Deprivation

Asian Journal of Andrology
MedicineUrology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy